Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone

Starting soon · Phase 3

Conditions studied: Giant Cell Arteritis (GCA)

In brief

The GISCO study plans to determine whether 8-week therapy is just as effective as 26-week cortisone therapy for treating giant cell arteritis * with tocilizumab, * while using less cortisone.

Key facts

Study ID

NCT06833411

Run by

Insel Gruppe AG, University Hospital Bern

People needed

178

Starts

2026-07-01

Expected to finish

2032-08-01

Last updated by the study team

2026-05-01

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with giant cell arteritis
• Start of tocilizumab treatment at baseline as part of routine clinical practice
• Receive ≥ 20 mg/day prednisone (or equivalent) at baseline
• Written informed consent

You may not qualify if…

• Treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) prior to the first dose of tocilizumab.

Where it is running

• Department of Rheumatology and Immunology, Inselspital, University of Bern — Bern, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.